In this sense, the use of Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors (such as olaparib) has been broadly used, since PARP is a key initiator of the repair by recruiting the DNA repair machinery to the site of damage.10,11 However, despite its preclinical data, dose escalation studies in phase I showed high hematologic toxicities that hampered its clinical use and limited its possibilities.12–21 Therefore, a strong rationale is needed to combine PARP inhibitors with other first-line treatment, especially in sarcoma, to further advance in this area of tumor treatment. Here, PARP1 is linked to sarcoma.